SWOT Analysis for Sutro Biopharma Inc

Relative Outperformance versus Industry over 1 Month
Stocks whose current price is 20% higher than week low, and more than previous close
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Increasing Revenue every quarter for the past 2 quarters
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Stock gained more than 20% in one month
Top Gainers
Stock with Low PE (PE < = 10)

Promoter decreasing their shareholding
Negative profit growth, promoters decreasing shareholding QoQ
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Low DVM Stocks - Stocks to Exercise Caution On
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Risky Value (DVM)
Low durability companies
Inefficient use of shareholder funds - ROE declining in the last 2 years
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Highest fall from 52 Week High
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Declining profits every quarter for the past 3 quarters
Stocks Underperforming their Industry Price Change in the Quarter